99mTechnetium-C595 radioimmunoscintigraphy: A potential staging tool for bladder cancer

BJU International

Volumn 88, Issue 7, 2001, Pages 686-691

  Simms, M S ^a,b   Perkins, A C ^a   Price, M R ^a   Scholfield, D P ^a   Bishop, M C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Immunoscintigraphy; MUC1; Staging

Indexed keywords

MONOCLONAL ANTIBODY C595 TC 99M; MUCIN 1; RADIOISOTOPE; UNCLASSIFIED DRUG; CA 15-3 ANTIGEN; DIAGNOSTIC AGENT; MUC1 MUCIN PEPTIDE; PEPTIDE FRAGMENT; TECHNETIUM;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; METASTASIS; PHOTON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RADIOIMMUNOASSAY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; CA-15-3 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PILOT PROJECTS; RADIOIMMUNODETECTION; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; URINARY BLADDER NEOPLASMS;

EID: 0035525573     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02348.x     Document Type: Article

References (19)

1. Voges G, Tauschke E, Stockle M et al. CT - an unreliable method for accurate staging of bladder tumours in patients who are candidates for radical cystectomy. J Urol 1989; 142: 972-4
2. Roy C, Lebras L, Mangold L et al. Small pelvic lymph node metastases: evaluation with MR imaging. Clin Rad 1997; 54: 437-40
3. Jager G, Barentsz J, Oosterhof G et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma. MR imaging with a 3D T1-weighted magnetization prepared rapid gradient echo sequence. Am J Radiol 1996; 167: 1503-7
4. Manyak MJ, Hinkle GH, Olsen JO et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54: 1058-63
5. Hughes OD, Bishop MC, Perkins AC et al. Targeting of superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000; 18: 363-70
6. Price MR, Pugh JA, Hudecz F et al. C595 - a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 1990; 61: 681-6
7. Petrakou E, Murray A, Price MR. Epitope mapping of anti-MUC1 protein core monoclonal antibodies. Tumour Biol 1998; 19 (Suppl. 1): 21-9
8. Hughes ODM, Denley H, Kunkler RB et al. MUC1 mucin expression in transitional cell carcinoma of the bladder - a target antigen for diagnosis and therapy with monoclonal antibody C595. J Urol Path 2001; in press
9. Kunkler RB, Bishop MC, Green DJ, Pimm MV, Price MR, Frier M. Targeting of bladder cancer with monoclonal antibody NCRC48 - a possible approach for intravesical therapy. Br J Urol 1995; 76: 81-6
10. 111indium labelled anti-MUC1 mucin monoclonal antibody C595. BJUInt 2001; 87: 39-46
11. Simms MS, Hughes ODM, Price MR, Perkins AC, Bishop MC. Technetium labelling of monoclonal antibody C595 for bladder cancer immunoscintigraphy: pre-clinical evaluation. BJU Int 1999; 84: 142
12. Begent RHJ, for the Joint Committee of the Cancer Research Campaign and National Institute for Biological Standards and Control. Operation Manual for control of production, preclinical toxicity and phase I trials of anti-tumour antibodies and drug antibody conjugates. Br J Cancer 1986; 54: 557-68
13. Mather SJ, Ellison D. Reduction-mediated technetium - 99m labelling of monoclonal antibodies. J Nucl Med 1990; 31: 692-7
14. Boeckmann W, Baum RP, Schuldes H et al. Tumour imaging of bladder carcinomas and their metastases with (111)In-labelled monoclonal anti-CEA antibody BW 431/26. Br J Cancer 1990; (Suppl. 10): 81-4
15. Behr TM, Becker WS, Sharkey RM et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996; 37: 829-33
16. Begent RHJ, Ledermann JA, Green AJ et al. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 1989; 60: 406-12
17. Loats H. CT and SPECT image registration and fusion for spatial localization of processes using radiolabelled monoclonals. J Nucl Med 1993; 34 (Suppl.): 562-6
18. Biassoni L, Granowska M, Carrol MJ et al. Evaluation of axillary lymph nodes in primary breast cancer with change detection statistical processing as an aid to tumour detection. Br J Cancer 1998; 77: 131-8
19. Quintana JC, Blend MJ. The dual isotope Prostascint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000; 25: 33-40